Analyst Ratings for Affirm Holdings

Within the last quarter, Affirm Holdings (NASDAQ:AFRM) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

Within the last quarter, Affirm Holdings (NASDAQ:AFRM) has observed the following analyst ratings:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 1 4 1 1
Last 30D 0 0 1 0 0
1M Ago 0 0 0 0 0
2M Ago 2 1 2 1 0
3M Ago 1 0 1 0 1

These 10 analysts have an average price target of $16.85 versus the current price of Affirm Holdings at $14.475, implying upside.

Below is a summary of how these 10 analysts rated Affirm Holdings over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This average price target has increased by 6.44% over the past month.

Stay up to date on Affirm Holdings analyst ratings.

How Are Analyst Ratings Determined?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Bristol Myers’ Expanded Approval For Anemia Drug, Shows Superior Efficacy Over Concurrent Blood Transfusion

On Monday, the FDA approved Bristol Myers Squibb Co's (NYSE: BMY) Reblozyl (luspatercept-aamt) for anemia without previous erythropoiesis-stimulating agent use (ESA-naïve) in adult patients with very low-to-intermediate-risk myelodysplastic syndromes (MDS) who may require regular 

BMY